The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Approaching patients with MF who are ineligible for SCT
Peter te Boekhorst, MD, PhD, Erasmus University Medical Center, Rotterdam, The Netherlands, discusses the management of patients with myelofibrosis (MF) who are ineligible for stem cell transplantation (SCT). Patients without any symptoms can be monitored until intervention is needed. Splenomegaly is treated with JAK inhibitors, and anemia can be managed with medications to elevate hemoglobin levels. The main challenge is low platelet counts, for which no effective medications currently exist. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
